0HI3.L AI Price Prediction

Track 0HI3.L's AI-powered predictions, market trends, and investment insights.

0HI3.L Sentiment 0HI3.L StockTwits 0HI3.L Reddit

Mock Tradesimulated, no real money

You don't hold 0HI3.L in your mock portfolio yet.

0HI3.L AI Price Prediction

Track 0HI3.L's AI-powered predictions, market trends, and investment insights.

0HI3.L Sentiment 0HI3.L StockTwits 0HI3.L Reddit

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)-0.7%

Price (7d)1.3%

Volume vs avg+4.4x

Reddit mentions vs 7D-100%

Volatility vs normal1.1x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

Low liquidity

Avg volume 1K — may be hard to exit

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~$71.33 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

0HI3.L AI Stock Analysis

Financial Performance

bearish

Arrowhead Pharmaceuticals remains unprofitable, as reflected by its negative EPS and PE ratio. The current valuation is based on future growth expectations rather than demonstrated earnings power, which heightens execution and clinical risk. Without clear evidence of improving profitability trends, the financial profile skews cautious despite potential in the pipeline.

Negative EPS of -1.08 and a PE ratio of -68.88 indicate ongoing losses and that the stock is valued on anticipated future earnings rather than current profitability.
The high-magnitude negative PE suggests the market is assigning a substantial premium to future growth, which is typical for clinical-stage or early-commercial biotech but increases downside risk if milestones slip.
Lack of positive earnings and margin visibility makes traditional profitability ratios weak, underscoring dependence on successful R&D, partnerships, and eventual commercialization to justify the current valuation.

Stock Price & Technicals

bullish

Despite a modest 3.9% pullback over the last month, Arrowhead’s stock trades well above its 200-day moving average, signaling a strong longer-term uptrend. The RSI near 50 suggests neither overbought nor oversold conditions, indicating a period of consolidation rather than exhaustion. Technically, the setup leans constructive as long as the price remains meaningfully above the long-term moving average.

Current price of $74.05 versus a 200-day moving average of $31.06 indicates the stock is trading in a strong longer-term uptrend, with substantial appreciation over the past several months.
A 3.9% decline over the last month reflects normal volatility and short-term consolidation rather than a clear breakdown in trend.
RSI at 50.61 is neutral, suggesting balanced buying and selling pressure and leaving room for either renewed upside or further consolidation without clear overbought/oversold signals.

Alternative Data Signals

bullish

Alternative data points show signs of operational expansion and steady external interest. A sharp month-over-month increase in job openings suggests active growth and investment in pipeline and operations. Web traffic and social media followings are modest but stable-to-growing, with LinkedIn presence indicating professional and industry engagement.

Job openings at 274, up 45.7% month over month, strongly suggest the company is scaling headcount, likely tied to R&D, clinical operations, and potential commercialization efforts—an expansionary and generally positive signal.
Estimated web traffic of 55,409 monthly visitors indicates a reasonable level of ongoing interest from investors, partners, patients, or professionals, consistent with a growing biotech profile.
Social media metrics show a relatively small but stable audience (3,825 on X, 506 on Facebook, 96,267 on LinkedIn) with slight growth on X and a large LinkedIn base, pointing to solid professional visibility even if retail/investor-focused engagement is only gradually increasing.

Conclusion

neutral

Arrowhead Pharmaceuticals exhibits strong technical momentum and expansionary alternative data signals, but its financial profile remains loss-making and highly dependent on future execution. The stock appears to be priced for growth, which could be rewarded if the pipeline delivers, but also leaves limited margin for error. Overall, the balance of promising operational signals against current unprofitability and valuation risk supports a neutral stance.

Technical strength (price far above the 200-day moving average and neutral RSI) and a sharp increase in job postings point to positive growth and operational momentum.
Persistent negative earnings and a high-magnitude negative PE ratio highlight fundamental risk and reliance on future clinical and commercial success, keeping the overall outlook neutral rather than clearly bullish.

AI Score

Hold

Alternative7

Fundamental7

Technical6

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold 0HI3.L in your mock portfolio yet.